NCT03136380View on ClinicalTrials.gov

Study of Danirixin in Japanese Healthy Elderly Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK1325756H

Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.

DRUG

Placebo

Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.

Trial Locations (2)

162-0053

GSK Investigational Site, Tokyo

162-00

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03136380 - Study of Danirixin in Japanese Healthy Elderly Male Subjects | Biotech Hunter | Biotech Hunter